Financial Statements of

MICHAEL SMITH FOUNDATION FOR HEALTH RESEARCH

(operating as Michael Smith Health Research BC)

And Independent Auditor's Report thereon

Year ended March 31, 2024



KPMG LLP

PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone 604 691 3000 Fax 604 691 3031

INDEPENDENT AUDITOR'S REPORT

To the Board of Michael Smith Foundation for Health Research

Opinion

We have audited the financial statements of Michael Smith Foundation for Health Research (operating as Michael Smith Health Research BC) (the "Organization") which comprise:

- the statement of financial position as at March 31, 2024
- the statement of operations for the year then ended;
- the statement of changes in net assets for the year then ended;
- the statement of cash flows for the year then ended;
- and notes to the financial statements, including a summary of significant accounting policies.

(hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as at March 31, 2024, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada. We have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Michael Smith Foundation for Health Research (operating as Michael Smith Health Research BC) Page 2

Emphasis of Matter – Comparative Information

We draw attention to Note 2(d) to the financial statements ("Note 2(d)"), which explains that certain comparative information presented for the year ended March 31, 2023 has been restated.

Note 2(d) explains the reason for the restatement and also explains the adjustments that were applied to restate certain comparative information.

Our opinion is not modified in respect of this matter.

Other Matter - Comparative Information

As part of our audit of the financial statements for the year ended March 31, 2024, we also audited the adjustments that were applied to restate certain comparative information presented for the year ended March 31, 2023. In our opinion, such adjustments are appropriate and have been properly applied.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Organization or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Organization's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.



Michael Smith Foundation for Health Research (operating as Michael Smith Health Research BC) Page 3

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on other legal and regulatory requirements

As required by the *Societies Act* (British Columbia), we report that, in our opinion, the accounting policies applied in preparing and presenting the financial statements in accordance with the Canadian accounting standards for not-for-profit organizations have been applied after giving retrospective effect to the change in accounting policy as explained in Note 2(d) to the financial statements, on a basis consistent with that of the preceding period.

Chartered Professional Accountants

Vancouver, Canada June 24, 2024

LPMG LLP

(operating as Michael Smith Health Research BC)

Statement of Financial Position

March 31, 2024, with comparative information for 2023

	2024	2023
		(restated - note 2(d))
Assets		11010 2(4))
Current assets:		
Cash and cash equivalents	\$ 9,512,444	\$ 6,319,813
Contributions and other amounts receivable	4,188,405	3,830,979
Short-term investments (note 3)	58,492,597	139,822,369
Prepaid expenses and deposits	184,024	76,270
	72,377,470	150,049,431
Long-term investments (note 3)	80,881,945	29,182,730
Capital assets (note 4)	529,758	491,533
Assets for implementation of software service (note 5)	208,037	130,677
	\$ 153,997,210	\$ 179,854,371
Current liabilities: Accounts payable and accrued liabilities Grants payable	\$ 1,286,273 780,030	\$ 1,140,334 621,250
	2,066,303	1,761,584
Deferred contributions (note 6):		
Contributions for expenses of future periods	141,505,225	166,009,734
Deferred capital contributions	737,795	622,210
Sponsored projects	6,368,722	8,141,678
	148,611,742	174,773,622
Net assets:		
Restricted for endowment purposes (note 3)	2,266,539	2,266,539
Unrestricted	1,052,626	1,052,626
Commitments (note 7)	3,319,165	3,319,165
	Ф 450 007 040	¢ 470.054.074
	\$ 153,997,210	\$ 179,854,371

The accompanying notes are an integral part of these financial statements.

Approved on behalf of the Foundation:

(operating as Michael Smith Health Research BC)

Statement of Operations

Year ended March 31, 2024, with comparative information for 2023

		2024	202	23
			(restate	
Revenue:			note 2((d))
Contributions recognized in current year (note 6(a))	\$	33,494,476	\$ 31,804,68	82
Contributions recognized in current year – sponsored	Ψ	00,404,470	Ψ 01,004,00	02
projects (note 6(c))		5,813,298	5,876,7	16
Amortization of deferred capital contributions (note 6(b))		231,026	250,40	
Other income		1,495,131	933,60	
		41,033,931	38,865,40	67
Expenses:				
Programs and projects:				
Scholar program		8,060,966	8,043,64	43
Program and project delivery expenses		6,038,520	4,845,18	
Sponsored project expenses		5,813,298	6,227,78	89
Partnership awards		5,171,091	3,702,04	
Health professional investigator program		4,073,264	3,491,9	
Research trainee program		3,993,994	3,471,3	
Other programs and projects		2,274,697	2,586,0	
Implementation science team program		497,599	80,7	
Convening and collaborating program		319,715	310,78	
Innovation to commercialization program		240,135	1,891,99	
Reach program		220,315	114,49	
Knowledge translation projects		73,631	42,1	
		36,777,225	34,808,12	28
Administration:				
General operating		4,025,680	3,806,93	34
Amortization of capital assets		168,964	231,60	69
Amortization of assets for implementation				
of software service		62,062	18,7	36
		4,256,706	4,057,33	39
		41,033,931	38,865,40	67
Excess of revenue over expenses	\$	-	\$	_

The accompanying notes are an integral part of these financial statements.

(operating as Michael Smith Health Research BC)

Statement of Changes in Net Assets

Year ended March 31, 2024, with comparative information for 2023

		Restricted for endowment	
2024	Unrestricted	purposes	Total
Net assets, beginning of year	\$ 1,052,626	\$ 2,266,539	\$ 3,319,165
Excess revenue over expenses	-	-	-
Net assets, end of year	\$ 1,052,626	\$ 2,266,539	\$ 3,319,165
		Restricted for endowment	
2023	Unrestricted	purposes	Total
Net assets, beginning of year	\$ 1,052,626	\$ 2,266,539	\$ 3,319,165
Excess revenue over expenses	-	-	-
Net assets, end of year	\$ 1,052,626	\$ 2,266,539	\$ 3,319,165

The accompanying notes are an integral part of these financial statements.

(operating as Michael Smith Health Research BC)

Statement of Cash Flows

Year ended March 31, 2024, with comparative information for 2023

		2024	2023
			(restated -
Cash provided by (used in):			note 2(d))
Cash flows from operating activities:			
Excess of revenue over expenses	\$	-	\$ -
Items not affecting cash:		400.004	004.000
Amortization of capital assets		168,964	231,669
Amortization of assets for implementation of software service		62,062	18,736
Amortization of deferred capital contributions		(231,026)	(250,405)
Amortization of deferred capital contributions		(231,020)	(230,403)
Changes in non-cash working capital:		_	_
Contributions and other amounts receivable		(357,426)	(3,048,554)
Prepaid expenses and deposits		(107,754)	97,629
Accounts payable and accrued liabilities		145,938	(386,023)
Grants payable		158,780	278,750
Contributions for expenses of future periods		(33,021,020)	(32,458,843)
Sponsored projects		(1,772,956)	(1,836,379))
Net cash used in operating activities		(34,954,438)	(37,353,420)
Investing activities:			
Purchase of capital assets		(207,189)	(30,100)
Purchase of assets for implementation		(207,100)	(00,100)
of software service		(139,422)	(81,793)
Purchase of short and long-term investments	(104,029,479)	(383,439,883)
Proceeds from sale of short and long-term investments		133,660,036	289,659,123
Investment income included in deferred			
contributions (note 6(a))		8,516,512	6,501,934
Net cash provided by (used in) investing activities		37,800,458	(87,390,719)
Financing activities:			
Deferred capital contributions allocated		346,611	111,893
·		-	
Net cash provided by financing activities		346,611	111,893
Net increase (decrease) in cash		3,192,631	(124,632,246)
Cash and cash equivalents, beginning of year		6,319,813	130,952,059
Cash and cash equivalents, end of year	\$	9,512,444	\$ 6,319,813

The accompanying notes are an integral part of these financial statements.

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

1. Nature of operations:

The Michael Smith Foundation for Health Research is incorporated under the *Societies Act* (British Columbia) and is a registered charity under the *Income Tax Act* (Canada), under the legal name Michael Smith Foundation for Health Research. Accordingly, the Organization is exempt from income and capital taxes and is able to issue donation receipts for income tax purposes.

The Organization's principal purpose is to:

- foster talent development so British Columbia can develop, attract, and retain the very best health researchers;
- support provincial health system priorities, health system transformation and innovation;
- · build capacity for research uptake; and
- optimize provincial health research investment through partnerships.

The Organization primarily receives funding from the Province of British Columbia (the "Province") to conduct a range of peer-reviewed grant programs and other projects. In addition, the Organization receives funding from other sources, including the Canadian Institute of Health Research ("CIHR"), to undertake various projects consistent with its purpose.

2. Significant accounting policies:

These financial statements have been prepared in accordance with Canadian Accounting Standards for Not-for-Profit Organizations and incorporate the following significant accounting policies:

(a) Cash and cash equivalents:

Cash and cash equivalents consist of cash and highly liquid short-term investments, which are defined as those having a maturity of less than three months from the date of acquisition.

(b) Revenue recognition:

The Organization follows the deferral method of accounting for contributions, including grants and donations from other sources.

Funding received from the Province, along with related future investment income, will be directed to the granting of funds to eligible recipients, the support of strategic initiatives and the payment of the Organization's operating and capital expenditures. These restricted contributions, along with any additional related grants and the investment income thereon, are initially deferred and subsequently recognized as revenue in the year in which the related expenses are incurred by the Organization. Restricted contributions used for the purchase of capital assets are deferred and amortized to revenue at a rate corresponding with the amortization rate for the related capital assets.

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

2. Significant accounting policies (continued):

(b) Revenue recognition (continued):

The Organization also receives various other restricted contributions through sponsored project grants, contracts or matching contributions from other Organizations such as CIHR that are deferred and recognized as revenue in the year in which the related expenses are incurred by the Organization.

Endowment contributions are recorded as a direct increase in net assets. Realized and unrealized investment income earned on endowment investments and restricted for specific purposes is deferred and recognized as revenue in the year in which the related expenses are incurred by the Organization.

Unrestricted contributions are recognized as revenue in the current period if the amount to be received can be reasonably estimated and collection is reasonably assured. Unrestricted investment income is recognized as revenue when earned.

(c) Capital assets:

Capital assets are recorded at cost less accumulated amortization. Repairs and maintenance costs are charged to expense. Other capital assets are amortized on a straight-line basis over their estimated useful lives as follows:

Computer software 3 years Website development 3 years Computer hardware 3 years Office furniture 5 years	Website development3 yearsComputer hardware3 yearsOffice furniture5 yearsOffice equipment5 years	Asset	Period
Office equipment 5 years Leasehold improvements Up to 10 years	Leasehold improvements Up to 10 years	Computer software Website development Computer hardware Office furniture Office equipment	3 years 3 years 3 years 5 years 5 years

Capital assets are assessed for impairment on an annual basis. When a decline is determined to be other than temporary, the amount of the loss is reported in the Statement of operations.

(d) Assets for implementation of software service and change in accounting policy:

Effective April 1, 2023, the Organization adopted AcG-20, Customer's accounting for cloud computing arrangements ("AcG-20").

Under AcG-20, the Organization has not elected to apply the simplification approach to account for expenditures in a cloud computing arrangement and has elected to capitalize the expenditures on implementation activities that are directly attributable to preparing the software service for its intended use as an asset. Capitalized expenditures are expensed on a straight-line basis over the expected period of access to the software service of 3 years.

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

2. Significant accounting policies (continued):

(d) Assets for implementation of software service and change in accounting policy (continued):

The Organization has elected to adopt AcG-20 retrospectively only to expenditures on implementation activities incurred in a cloud computing arrangement on or after April 1, 2022. Accordingly, as of March 31, 2023, \$149,412 was reclassified from capital assets to assets for implementation of software service on the statement of financial position and note 4 has been restated for this reclassification. There was no impact to total assets or total net assets as of March 31, 2023 and no impact to excess of revenue over expenses for the year ended March 31, 2023 as a result of the adoption of AcG-20.

(e) Financial instruments:

Financial instruments are initially measured at fair value. Subsequently, equity instruments quoted in an active market are measured at fair value. Other instruments are subsequently measured at amortized cost unless elected to be measured at fair value. The Organization has elected to carry its investments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Financial assets measured at amortized cost are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Organization determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Organization expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

The Organization's financial instruments consist of cash, contributions and other amounts receivable, short- term and long-term investments, accounts payable and accrued liabilities and grants payable.

- (i) Contributions and other amounts receivable are measured at amortized cost using the effective interest method and approximate their fair values due to the relatively short periods to maturity.
- (ii) Investments:
 - (A) Short-term investments include any term deposits, income funds, bonds or equities, with a term to maturity of less than one year.

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

2. Significant accounting policies (continued):

- (e) Financial instruments (continued):
 - (ii) Investments (continued):
 - (A) Short-term investments (continued) Short-term investments are measured at fair value with subsequent changes to fair value recorded as changes in deferred contributions and recognized as revenue when the related expenses are incurred.
 - (B) Long-term investments include any term deposits, bonds and equities with a term to maturity of more than one year or that are related to permanent endowments. Longterm investments are measured at fair value with subsequent changes in fair value recorded as changes in deferred contributions and recognized as revenue when the related expenses are incurred.
 - (iii) Financial liabilities such as accounts payable and accrued liabilities and, grants payable are measured at amortized cost using the effective interest method
- (f) Grants and awards:

Grants and awards approved by the Organization are recorded as expenses in the fiscal year that the expense is incurred, or the obligation arises. Amounts are usually paid in quarterly instalments in advance.

(g) Volunteer services:

The Organization gratefully acknowledges the significant contribution it receives in the form of services from a large number of volunteer peer reviewers, committee members and task force participants. Such services, while essential to the Organization's operations, are not recorded in these financial statements because of the difficulty of determining their fair value.

(h) Employee pension plan:

The Organization's employees belong to the Municipal Pension Plan, which is a multi-employer contributory pension plan. The Organization records its pension expense as the amount of employer contributions made during the fiscal year (defined contribution pension plan accounting). This is because the plan records accrued liabilities and accrued assets for the plan in aggregate, resulting in no consistent and reliable basis for allocating the obligation, assets, and costs to individual employers participating in the plan.

(i) Measurement uncertainty:

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenue and expenses during the reporting period. Areas requiring the use of management estimates relate to the established useful lives of capital assets and assets for implementation of software service. Actual results could differ from those estimates.

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

3. Investments:

	2024	2023
Income funds	\$ 25,160,591	\$ 42,607,934
Term deposits Equities	109,000,000 5,213,951	91,000,000 16,823,285
Bonds	139,374,542	18,573,880 169,005,099
Less: short-term	58,492,597	139,822,369
Long-term	\$ 80,881,945	\$ 29,182,730

Investments in term deposits have maturity dates ranging from fiscal 2024 to fiscal 2028. The long-term portion consists of deposits with maturity dates beyond the next fiscal year and the holdings that are related to the endowment fund.

At March 31, 2024, the market value of endowment fund investments was \$4,711,170 (2023 - \$4,225,335) based on a book value of net asset endowment contributions of \$2,266,539 (2023 - \$2,266,539).

4. Capital assets:

				2024	2023
	Accumulated		Net book	Net book	
	Cost	an	nortization	value	value
					(restated - note 2(d))
Computer software	\$ 951,867	\$	926,451	\$ 25,416	\$ 93,486
Website development	62,884		60,526	2,358	18,551
Computer hardware	418,017		395,504	22,513	33,661
Office furniture and equipment	245,234		211,974	33,260	24,093
Leasehold improvements	712,439		266,228	446,211	321,742
	\$ 2,390,441	\$	1,860,683	\$ 529,758	\$ 491,533

5. Assets for implementation of software service:

				2024	2023
		Ac	cumulated	Net book	Net book
	Cost	ar	mortization	value	value
A contract for invalid and the second of the					(restated – note 2(d))
Assets for implementation of software service	\$ 288,835	\$	80,798	\$ 208,037	\$ 130,677

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

5. Assets for implementation of software service (continued):

During the year ended March 31, 2024, included in general operating expense on the Statement of Operations is licensing fees incurred of \$32,164 (2023 - \$2,023) and amortization of assets for implementation of software service of \$62,062 (2023 - \$18,736).

6. Deferred contributions:

Deferred contributions represent unspent grants or contract resources restricted for specific purposes and projects, and include expenses for operating, as well as capital purposes.

(a) Deferred contributions relating to expenses of future periods:

	2024	2023
Balance, beginning of year	\$ 166,009,734	\$ 191,966,643
Increases during the year:		
Federal and other grants	895,843	1,217,767
Investment income	8,516,512	6,501,934
Unrealized loss on investments	(75,777)	(1,760,035)
	175,346,312	197,926,309
Amounts recognized as revenue during the period Amounts applied toward capital assets and asset for implementation of software service purchased	(33,494,476)	(31,804,682)
during the period	(346,611)	(111,893)
Balance, end of year	\$ 141,505,225	\$ 166,009,734

(b) Deferred capital contributions:

	2024	2023
Balance, beginning of year Allocation of deferred capital contributions Amounts amortized to revenue	\$ 622,210 346,611 (231,026)	\$ 760,722 111,893 (250,405)
Balance, end of year	\$ 737,795	\$ 622,210

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

6. Deferred contributions (continued):

(c) Deferred contributions relating to sponsored projects:

2024	Balance beginnin of the yea	donation	Amounts recognized	Balance, end of the year
BC Influenza Vaccine Program Health Services and Policy Research Support BC Nursing Research Initiative COVID-19	\$ 52,42 55,48 18,42 208.86	- -	\$ - - - (169,880)	\$ 52,423 55,484 18,426 38,989
Children and Youth with Special Needs Interior Health Capacity Building Human Papillomavirus 2	381,62 3,74 237,23	- 3 - 5 -	(141,350) - -	240,270 3,748 237,236
Alzheimer's Disease Research BC SUPPORT Unit	83,63 7,100,24 \$ 8,141,67	1 4,040,342	(5,502,068) \$ (5,813,298)	83,631 5,638,515 \$ 6,368,722

2023	be	Balance, eginning the year		ntributions and donation o revenue	Amounts recognized	Balance, end of the year
BC Influenza Vaccine Program Health Services and Policy Research Support	\$	52,423 55,484	\$	-	\$ -	\$ 52,423 55,484
BC Nursing Research Initiative		18.426		-	-	18.426
COVID-19		305.994		_	(97,125)	208.869
Children and Youth with Special Needs		381,620		_	(01,120)	381,620
Interior Health Capacity Building		3,748		-	-	3,748
Human Papillomavirus 2		237,236		-	-	237,236
Alzheimer's Disease Research		83,631		-	-	83,631
BC SUPPORT Unit	8,	283,912		4,040,337	(5,224,008)	7,100,241
Long-term care – Quality Improvement		308,344		-	(308,344)	-
Clinician Fellowship in Health Care Quality		247,239		-	(247,239)	-
	\$ 9,	978,057	\$ 4	4,040,337	\$ (5,876,716)	\$ 8,141,678

7. Commitments:

(a) Grant commitments:

Through a variety of targeted granting programs, the Organization commits the majority of its funds to providing peer-reviewed research awards or strategic projects aimed at fulfilling the Organization's mandate. Some of the commitments made through these granting programs and projects have terms that span more than one fiscal year. Such grants have ongoing eligibility criteria and, consequently, grant commitments are expensed in the period that the expense is incurred or the obligation arises.

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

7. Commitments (continued):

(a) Grant commitments (continued):

The following table summarizes grant commitments approved by the Organization, by major grant program or project, funded by the unrestricted deferred contributions from note 6(a):

	Grant commitments for the years ending March 31 2026 and					
		2025		thereafter		Total
Grant programs: Scholar program Research trainee program Health Professional investigator program Innovation to commercialization program Partnership awards	\$	426,250 846,583 2,415,000 433,703 3,750	\$	120,000 - - - 62,500	\$	546,250 846,583 2,415,000 433,703 66,250
	\$	4,125,286	\$	182,500	\$	4,307,786

(b) Grant commitments - Sponsored projects:

Through a variety of specialized granting programs, the Organization also may commit significant amounts of project funding to providing peer-reviewed research awards aimed at fulfilling each project's specific mandate. Some of the commitments made through these granting programs have terms that span more than one fiscal year. Such grants have ongoing eligibility criteria and, consequently, grant commitments are expensed in the period that the expense is incurred or the obligation arises.

There are no significant commitments for sponsored projects.

(c) Office space and equipment lease commitments:

The Organization rents two office spaces. The space at 1285 West Broadway is under a long-term lease that expires October 31, 2028 and provides for an additional five-year extension at the option of the Organization. The space at 1367 West Broadway is under a long-term lease that expires October 31, 2026 and provides for an additional five-year extension at the option of the Organization.

The Organization has future minimum lease payments under these operating leases as follows.

Years ending March 31:	
2025	\$ 781,375
2026	795.462
2027	707,471
2028	564,721
2029	333,673
	\$ 3,182,702

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

8. Financial risk management:

(a) Credit risk:

Credit risk is the risk of financial loss to the Organization if a counterparty to a financial instrument fails to meet its contractual obligations. The Organization's cash and investments in any term deposits, bonds, income funds and equities are subject to credit risk. The maximum exposure to credit risk on these instruments is their carrying value. The Organization manages the risk by retaining professional investment counselors who act in accordance with the Organization's investment policies. These policies include asset mix guidelines and minimum investment grade levels for each asset class. The Organization has deposited cash with reputable financial institutions, from which management believes the risk of loss to be remote.

Other credit risks can arise from holding receivables. The Organization has minimal accounts receivable, other than from government and, as such, the credit risk is minimal.

(b) Liquidity risk:

Liquidity risk is the risk that the Organization will not be able to meet its financial obligations as they fall due. A significant portion of the Organization's assets are held as short-term investments that can be readily liquidated and, therefore, the Organization's liquidity risk is considered minimal. In addition, the Organization aims to retain a sufficient cash position to manage liquidity.

(c) Market risk:

Market risk is the risk that changes in market prices, as a result of changes in foreign exchange rates, interest rates and equity prices, will affect the Organization's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters while earning an acceptable return.

(i) Currency risk:

Investments in foreign securities are exposed to currency risk due to fluctuations in foreign exchange rates.

The Organization holds minimal investments in foreign currencies; as such, the risk is minimal.

(ii) Interest rate risk:

Interest rate risk relates to the risk that changes in interest rates will affect the fair value or future cash flows of financial instruments held by the Organization. The Organization is invested in term deposits and income funds that may be impacted by changes in the market interest rate.

The Organization manages interest rate risk on term deposits by choosing instruments that have fixed rates of return and terms that will match the projected cash flow requirements. Interest rate risk on income funds is managed through professional investment counselors, by holding instruments that have a high liquidity in the marketplace or by choosing instruments with fixed terms that align with projected cash flow requirements.

There has been no change to the risk exposure from the prior year.

(operating as Michael Smith Health Research BC)

Notes to Financial Statements

Year ended March 31, 2024

9. Employee pension plan:

The Organization and its employees contribute to the Municipal Pension Plan (jointly trusteed pension). The Boards of Trustees, representing plan members and employers, is responsible for administering the pension plan, including investing assets and administering benefits. The plan is a multi-employer defined benefit pension plan. Basic pension benefits are based on a formula. As at December 31, 2022, the plan has about 240,000 active members and approximately 124,000 retired members.

Every three years, an actuarial valuation is performed to assess the financial position of the plan and adequacy of plan funding. The actuary determines an appropriate combined employer and member contribution rate to fund the plan. The actuary's calculated contribution rate is based on the entry-age normal cost method, which produces the long-term rate of member and employer contributions sufficient to provide benefits for average future entrants to the plan. This rate may be adjusted for the amortization of any actuarial funding surplus and will be adjusted for the amortization of any unfunded actuarial liability.

The latest actuarial valuation for the Municipal Pension Plan as at December 31, 2021 indicated a \$3,761 million funding surplus for basic pension benefits. The next valuation will be as at December 31, 2024, with results available in 2025.

The Organization paid \$648,382 for employer contributions to the plan during the year ended March 31, 2024 (2023 - \$480,138).

10. Remuneration:

(a) Remuneration of Directors:

The Directors of the Organization are not remunerated.

(b) Employees and contractors for services that are individually greater than \$75,000:

During the year ended March 31, 2024, the Organization paid total remuneration (including taxable benefits) of \$5,290,967 (2023 - \$3,589,951) to 43 employees and contractors (2023 - 32) for services whose individual remuneration was at least \$75,000.